Brazil will receive supplies to produce Oxford s COVID-19 vaccines
Brazil will receive supplies to produce Oxford s COVID-19 vaccines
Brasilia, Feb 27 (Prensa Latina) The Government of Brazil will receive on Saturday raw material to produce 12 million Covid-19 vaccines developed by the University of Oxford (United Kingdom) and the Anglo-Swedish company AstraZeneca in a national laboratory.
The so-called Active Pharmaceutical Ingredients (API) manufactured by the Wuxi Biologics laboratory, in China, will be stored at the Oswaldo Cruz Institute (Fiocruz), in Rio de Janeiro, the Ministries of Health and Foreign Relations reported.
This will be the second batch of APIs arriving in the country to produce the AstraZeneca vaccine. Brazil received from China the first batch of ingredient on January 6th.
Emergex Vaccines Holding Ltd: Emergex Strengthens Senior Management Team
Emergex Strengthens Senior Management Team
Appointments of Mr Robin Cohen as Business Development Director and Ms Susi Osborne as Manufacturing Director
Abingdon, Oxon, UK, 23 February 2021 - Emergex Vaccines Holding Limited ( Emergex , or the Company ), a company tackling major global infectious disease threats through the development of synthetic set point vaccines which prime the T-Cell immune response, today announces the appointment of Mr Robin Cohen, as Business Development Director. The Company is also pleased to announce the appointment of Ms Susi Osborne as Manufacturing Director, who joined Emergex in January this year.
Brasilia, Jan 6 (Prensa Latina) Brazil will receive from China the first batch of the Active Pharmaceutical Ingredient (API) for the production of the anti-Covid-19 vaccine developed by the University of Oxford (UK) and the Anglo-Swedish company AstraZeneca.
3 min read
The administering of a fraction of the standard yellow fever vaccine is effective and could help vaccinate millions of people during emergencies, a new study has shown.
The study led by the research arm of Doctors Without Borders/Médecins Sans Frontiéres’ (MSF), Epicentre, and published in The Lancet shows that fractioning doses of the yellow fever vaccine is effective and safe.
According to the study, giving a person one-fifth of the vaccine dose is safe and could prevent people from getting sick from the disease.
“These clinical trial results found that giving a person one-fifth of the standard yellow fever vaccine dose is effective and safe,” MSF said in a statement published on its website.
13 Jan 21
WHO will change its guidelines to recommend using partial doses of the yellow fever vaccine during emergencies as a result of new clinical trial data.
Giving people a fraction of a yellow fever vaccine is effective and could help vaccinate millions more people during emergencies, according to results of a recent study led by Doctors Without Borders/Médecins Sans Frontiéres’ (MSF) research arm Epicentre, published in The Lancet.
These clinical trial results, which found that giving a person one-fifth of the standard yellow fever vaccine dose is effective and safe, will make it easier for governments and international organizations to prevent people from getting sick from yellow fever during outbreaks in times of vaccine shortage.